Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 17/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | ITK | Q08881 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5779395 | 0.90 | CNR2 (0.69) | CNR2PTK2EGFRITK | |
| SCHEMBL5781933 | 0.87 | CNR2 (0.69) | CNR2CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL5077181 | 0.86 | CNR2 (0.69) | CNR2CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL5083384 | 0.86 | CNR2 (0.69) | CNR2CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL3378844 | 0.83 | CNR2 (0.74) | CNR2CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL5779533 | 0.83 | CNR2 (0.55) | CNR2CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL5780485 | 0.83 | CNR2 (1.00) | CNR2CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL5776710 | 0.83 | CNR2 (0.58) | CNR2CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL5780255 | 0.82 | CNR2 (0.68) | CNR2CYP1A2CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL5080774 | 0.81 | CNR2 (0.56) | CNR2EGFRITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1736470-A2 | Pyrimidine derivatives as CB2 cannabinoid receptor modulators | GLAXO GROUP LIMITED (GB) | 2006-12-27 | — | — | EP | disclosed |